€200,000 grant from ICEX, Invest in Spain and European Regional Development Fund will support ongoing CANNABI+ project developing cannabis varieties with unique cannabinoid and terpene profiles
Madrid, Spain, 4 July 2022: Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and wellbeing, today announces it has received a €200,000 grant from the ICEX, Invest in Spain framework, with co-financing from the European Regional Development Fund (ERDF), to support the Company’s ongoing CANNABI+ project exploring the research and cultivation of novel cannabis varieties with a high content of cannabinoids and specific terpene profiles, for the development of medicinal cannabis products.
While the potential health effects of cannabinoid compounds found within cannabis, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), have been an active area of research for many years, scientists are now exploring their combined therapeutic potential with terpenes, the compounds in cannabis that give its distinctive aroma.
Linneo Health was supported in this research by the Molecular Genetics group of the Instituto de Biotecnología Vegetal at the Universidad Politécnica de Cartagena (UPCT), using the latest and most innovative techniques. As a result of this research, Linneo Health strengthens its portfolio with new and interesting varieties that will be cultivated consistently, upholding Linneo’s commitment to the delivery of medicinal cannabis with the highest quality and standard.
These newly developed cannabis varieties, tailored to contain the optimal cannabinoid and terpene content depending on their intended use, have the potential to be used in the development of medicinal cannabis products across a wide range of therapeutic areas, to treat conditions such as metabolic syndrome or to provide anticonvulsant effects for conditions such as epilepsy. Further experiments may identify lines suitable to inhibit vomiting syndrome in patients undergoing chemotherapy.
Don Bellamy, Chief Executive Officer of Linneo Health, said: “We are proud to have been awarded the maximum grant of €200,000 by ICEX, Invest in Spain and the European Regional Development Fund, following their thorough review process, to support the continuation of CANNABI+.
“This ambitious project aims to develop new cannabis varieties with specific cannabinoid and terpene profiles which have the potential to support our partners in the development of novel medicinal cannabis products that can provide new treatment options for multiple medical conditions. This grant and the CANNABI+ project demonstrate Linneo’s commitment to continuous innovation to deliver the cutting edge in medicinal cannabis, to improve human health and wellbeing.”
Don Bellamy, CEO
Tel: +34 91 700 20 90
Consilium Strategic Communications
Amber Fennell / David Daley / Maya Bennison
Tel: +44 (0) 20 3709 5700
About Linneo Health
Linneo Health is a global leader in the research, EU-GMP certified manufacture and supply of medicinal cannabis flowers, extracts and products to pharmaceutical partners developing innovative cannabis-based therapies for patients in need. The world’s only vertically integrated medicinal cannabis supplier, no other company has Linneo’s 90-year heritage in the manufacturing, handling and movement of controlled substances. Linneo is optimally positioned to address the needs of its customers through every stage of product development, regulation and handling.
Linneo Health is setting the benchmark for standards and customer service in medicinal cannabis. Through ongoing investment in one of the most advanced quality control laboratories in Europe, and by applying industry-leading cultivation techniques, Linneo is the trusted partner to address the needs of customers today and, with significant expansion capabilities, the demands of tomorrow. With an unrivalled focus on quality and driven by the firm belief that people around the world deserve to be treated with cannabis medicine of the highest standard, Linneo brings cutting edge innovation in medicinal cannabis to partners, to deliver better patient outcomes and improve lives.